Toggle Main Menu Toggle Search

Open Access padlockePrints

Robotic lateral oropharyngectomy following diagnostic tonsillectomy is oncologically safe in patients with human papillomavirus-related squamous cell cancer: Long-term results

Lookup NU author(s): Daniel Lin, Dr Max RobinsonORCiD, Professor Vinidh Paleri

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

© 2022 Wiley Periodicals LLC.Introduction: To report the long-term oncological and functional outcomes of en bloc TORS lateral oropharyngectomy to address the close/involved margin following diagnostic tonsillectomy in HPV-related SCC of unknown primary. Material and methods: A single tertiary center observational cohort over a 4-year period. Primary outcome measures were disease-specific survival (DSS), overall survival (OS), and PSS NOD (Performance Status Scale-Normalcy of Diet) scores. Results: TORS specimens did not evidence residual carcinoma in 93% of patients. Of 14 patients, 50% received surgery alone (median follow-up 57 months; range 46–96), the remainder surgery and adjuvant therapy (median follow-up of 58 months; range 51–69) with 100% DSS, OS and no deterioration of PSS NOD scores. Conclusions: Long-term oncological outcomes confirm TORS lateral oropharyngectomy alone is an oncologically safe treatment. Due consideration of this approach is warranted to mitigate against the morbidity of adjuvant radiotherapy treatment in this group of patients.


Publication metadata

Author(s): Siddiq S, Stephen S, Lin D, Fox H, Robinson M, Paleri V

Publication type: Article

Publication status: Published

Journal: Head and Neck

Year: 2022

Volume: 44

Issue: 12

Pages: 2753-2759

Print publication date: 01/12/2022

Online publication date: 03/09/2022

Acceptance date: 23/08/2022

ISSN (print): 1043-3074

ISSN (electronic): 1097-0347

Publisher: John Wiley and Sons Inc

URL: https://doi.org/10.1002/hed.27186

DOI: 10.1002/hed.27186

PubMed id: 36056651


Altmetrics

Altmetrics provided by Altmetric


Share